Evaluation of Respiratory Parameters and Functional Capacity in Coronary Artery Patients

Coronary Artery Disease Clinical Trial

Official title:

Evaluation of Respiratory Parameters and Functional Capacity in Coronary Artery Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05549739
• Other study ID #: GO 20/298
• Status: Active, not recruiting
• Start date: September 23, 2022
• Est. completion date: November 2022

Study information

• Verified date: October 2022
• Source: Hacettepe University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this study is to evaluate respiratory parameters and functional capacity in coronary artery patients.

Description:

Decreased pulmonary function as measured by forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), or peak expiratory flow (PEF) has been associated with an increased risk of cardiovascular mortality and morbidity. A low MIP value may generally indicate weak muscle strength and therefore be an indicator of general poor health. Respiratory muscle weakness and decreased respiratory muscle endurance affect exercise tolerance in individuals with chronic disease, including cardiovascular disease. Studies have supported the association of grip strength with frailty, physical activity, diabetes, functional limitation, nutritional status, metabolic syndrome, and mortality.

The study will evaluate respiratory parameters and functional capacity in coronary artery patients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: November 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 41 Years to 75 Years

Eligibility

Inclusion Criteria:

• Patients with coronary artery disease

• Volunteering to participate in the research

Exclusion Criteria:

• Having a musculoskeletal problem

• Having unstable cardiac disease

• Having chronic heart failure (NYHA III-IV)

• A history of acute coronary syndrome or surgical revascularization less than 3 months ago

• Having arrhythmia

• Having the last stage of kidney disease

• Having active myocarditis or pericarditis

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Locations

Country	Name	City	State
Turkey	Hacettepe University	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Hacettepe University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Six-minute-step test	The number of steps the participant climbed up and down is recorded.	Day 1
Primary	Respiratory muscle strength	Respiratory muscle strength will be evaluated using a mouth pressure device.	Day 1
Primary	Respiratory muscle endurance	Respiratory muscle endurance will be evaluated using a constant load test.	Day 1
Secondary	Pulmonary functions	Forced vital capacity (FVC), Forced expiratory volume at one second (FEV1), Peak expiratory flow (PEF) assessment via spirometry.	Day 1
Secondary	Hand grip strength	Hand grip strength is evaluated by a hand dynamometer.	Day 1
Secondary	Functional Capasity	The functional capacity is assessed with The Duke Activity Status Index (DASI).	Day 1